The use of immunotherapy for the treatment of tuberculosis

• Published in: Expert review of respiratory medicine Vol. 12; no. 5; p. 427
• Main Authors: Ramos-Espinosa, Octavio, Islas-Weinstein, León, Peralta-Álvarez, Marco Polo, López-Torres, Manuel Othoniel, Hernández-Pando, Rogelio
• Format: Journal Article
• Language: English
• Published: England 04.05.2018
• Subjects: Animals; Humans; Immunotherapy; Tuberculosis, Pulmonary - therapy; pulmonary tuberculosis; Antibodies; gene therapy; cytokines; cell therapy; antimicrobial peptides
• ISSN: 1747-6356
• DOI: 10.1080/17476348.2018.1457439

Tuberculosis (TB) is the first cause of mortality by a single infectious agent in the world, causing more than one million deaths worldwide as reported by the World Health Organization (WHO). For the optimal control of TB infection, a protective immune response that limits bacterial spread without causing damage to the host is essential. Although most healthy individuals are capable of generating protective responses, patients who suffer pulmonary TB commonly present a defective immune function. Areas covered: We intend to highlight the potential of novel immunotherapeutic strategies that enhance and promote effective immune responses. The following methodology was undertaken for establishing a literature search: the authors used PubMed to search for 'Pulmonary Tuberculosis' and keywords that denoted the novel immunotherapeutic strategies discussed in length in the text including antibodies, antimicrobial peptides, cell therapy, cytokines and gene therapy. Expert commentary: The current therapeutic regimens for this disease are complex and involve the prolonged use of multiple antibiotics with diverse side effects that lead to therapeutic failure and bacterial resistance. The standard appliance of immunotherapy and its deployment to vulnerable populations will require coordinated work and may serve as a powerful tool to combat the ensuing threat of TB.